AIM-HIV PROJECT------------------------Instituto Salud Carlos III

Why a microbicide?

Sexual intercourse is the main mode of HIV transmission among adults globally. We now understand that sexual transmission of HIV is determined by a range of factors that influence the probability of transmission during a specific sexual encounter including HIV viral load, stage of HIV disease, sexually transmitted infections (STIs) and other genital infections and male circumcision.

Although biological factors are important for HIV transmission, they are in turn influenced by a complex array of underlying factors including societal and cultural norms, sex-based inequality and socioeconomic variables. Studies of the epidemiology of HIV have highlighted the increased vulnerability of women to HIV infection. Although the male condom is highly effective in preventing the sexual transmission of HIV, in many settings, women have little negotiating power to use a condom and protect themselves against HIV. Highly active antiretroviral therapy (HAART), if given to all HIV-positive individuals, could bring the pandemic under control, but in 2012, only 9.7 million people living with HIV had access to antiretroviral therapy in low and middle income conuntries. This represent 61% of people eligible for treatment under the 2010 WHO guidelines and 34% of people eligible under the 2013 WHO guidelines. In addition, the number of new infections in 2012 (2.3 million people) are still higher then the increase in the number of people taking antiretroviral therapy (1.6 million people).

As a consequence, among the different strategies proposed to prevent and decrease the rate of transmission of HIV, the use of microbicides is a major goal in countries with high incidence of poverty-related diseases, being particularly important in the social context of African women and other women of poverty areas.

NEWS 01  


Productive HIV-1 infection of human cervical tissue ex vivo is associated with the secretory phase of menstrual cycle. Read more.    




10/01/2014. The partners of the project and the Scientific Advisory Board attended the Progress Meeting of the project in Madrid.  



October 7-10, 2013. ISCIII and SEPROX presented an oral communication and a poster in the AIDS Vaccine Conference. Read more.


Instituto de Salud Carlos III. 2013. All rights reserved

This project has received funding from the European Union’s Seventh Framework Programme for research, technological development and demonstration under grant agreement no 305938.

Web Map  Legal AdviceAccesibility | Contact

cea unisr seprox biotech IscIII